About Von Willebrand Disease — What is VWD
The Humate-P® Difference: High Quality & Quantity

How Clotting Works
Efficacy
Safety
Convenience
Home Infusion Video
Mix2Vial™ Needle-Free transfer Device
The CSL Behring Commitment
Resources and Tools
News & Events
Important Safety Information
Prescribing Information
Request More Information
For Healthcare Professionals
      

The Humate-P® Difference: High Quality & Quantity

Humate-P is called a von Willebrand factor (VWF) replacement therapy because it replaces the VWF in your blood that is missing or that doesn't work properly. VWF is a protein in your blood that helps blood to clot properly. (Click here for an overview of How Clotting Works)

Humate-P® is indicated in adult and pediatric patients with VWD for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate.

Humate-P® has the high quality (HMWMs) and high quantity (2.4:1 ratio) of VWF, which are important in the effective treatment of von Willebrand disease (VWD).

What you should know about the quality and quantity of VWF replacement therapy:

  • Your VWF replacement therapy should resemble the VWF in normal human blood as closely as possible, to be as effective as possible
  • The VWF in normal human blood has a high percentage of high molecular weight multimers (HMWMs)
  • Among VWF-containing concentrates, Humate-P® has the most HMWMs, closely resembling the VWF in normal human blood.1,3

Important Safety Information

Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized, Humate-P® is indicated in adult patients for treatment and prevention of bleeding in hemophilia A (classical hemophilia). Humate-P® is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate.

Humate-P® is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations, or to any of its components.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement, especially in the setting of known risk factors for thrombosis. Caution should be exercised and antithrombotic measures considered.

Humate-P® is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

The most common adverse reactions reported in patients receiving Humate-P® are allergic-anaphylactic reactions, including urticaria, chest tightness, rash, pruritus, edema, shock, chills and fever, and hypervolemia. For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

References

  1. Berntorp E, Nilsson IM. Biochemical and in vivo properties of commercial virus-inactivated factor VIII concentrates. Eur J Haematol. 1988;40:205-214.
  2. Metzner HJ, Hermentin P, Cuesta-Linker T, Langner S, Müller H-G, Friedbold J. Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis. Hemophilia. 1998;4(suppl 3):25-32.
  3. Berntorp E, Nilsson IM. Use of a high-purity factor VIII concentrate (Hemate P) in von Willebrand's disease. Vox Sang. 1989;56:212-217.